Trials / Terminated
TerminatedNCT02004392
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 348 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVP-6124 |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-08-01
- Completion
- 2017-08-01
- First posted
- 2013-12-09
- Last updated
- 2016-05-03
Locations
86 sites across 12 countries: United States, Australia, Belgium, Canada, Czechia, Italy, Netherlands, Poland, South Africa, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02004392. Inclusion in this directory is not an endorsement.